SS-31, also known as elamipretide, holds a split regulatory status as of late 2025. The FDA approved it for one rare-disease indication in September 2025, while every other use remains investigational and unapproved by any major regulator. The compound sold online under the SS-31 name is not that approved prescription product but an unapproved chemical that is not lawful to administer to people.
SS-31 (elamipretide) carries a split status - FDA-approved only as the prescription Barth syndrome drug FORZINITY since September 2025, and investigational, unapproved, and unlawful to administer to humans for every other use.
Marketing approval is a specific legal threshold, and elamipretide has crossed it for exactly one use. The September 2025 FORZINITY approval covers Barth syndrome; late-stage trials in other mitochondrial conditions have not cleared the bar. Designations such as orphan-drug or fast-track status shape the review process without granting any permission to market.
| Status | Investigational drug | Approved drug |
|---|---|---|
| Permission | Allowed only inside sanctioned studies | Cleared for a defined use and labeling |
| Evidence standard | Safety and efficacy still being established | Benefits judged to outweigh risks |
| SS-31 today | Every use except Barth syndrome | FORZINITY for Barth syndrome only |
Elamipretide holds a single marketing approval worldwide - FDA accelerated approval as FORZINITY for Barth syndrome in September 2025 - and carries no approval from the FDA, EMA, or any equivalent authority for any other use.
The "research use only" designation began as a legitimate category for laboratory reference chemicals never meant to enter a person. In the peptide marketplace it is frequently repurposed as a disclaimer that lets a seller offer a compound while formally denying it is a medicine, which sidesteps the approval, prescribing, and manufacturing obligations a drug would trigger.
A "research use only" label is a statement about legal posture, not a quality certification, and it sets no floor for a product's identity, purity, sterility, or concentration.
The law treats the actions around an unapproved compound very differently, and the treatment shifts by location, so no single answer fits. Selling carries the clearest exposure, personal possession is often grayer but not guaranteed safe, and importing adds a customs layer of its own.
Distributing an unapproved drug carries the clearest legal exposure, personal possession sits in a grayer and jurisdiction-dependent zone, and a "research use only" label on an order does not convert personal human use into a sanctioned activity.
Regulatory status is not a global constant; each jurisdiction stitches it together from its own medicines law, enforcement priorities, and border controls. Apart from the FDA's narrow 2025 approval of elamipretide as FORZINITY, no regulator in a major market has authorized SS-31 for general sale.
| Jurisdiction | Governing framework | Effect on an unapproved compound |
|---|---|---|
| United States | FDA new-drug authority | Human use generally needs an IND pathway; treatment marketing barred |
| European Union | EMA and national authorities | Without marketing authorization it cannot be legally placed on the market |
| Other countries | Local health and import regimes | Availability and border interception vary widely |
Apart from the FDA's narrow 2025 approval of elamipretide as FORZINITY, no regulator in a major market has authorized SS-31 for general sale, and the mechanics of restriction and enforcement differ by jurisdiction and keep changing.
A seller's legal position hinges less on the molecule than on how it is presented. The moment a compound is marketed for human use or attached to a claim that it treats, prevents, or improves a condition, most drug frameworks pull it into the definition of an unapproved and often misbranded drug.
Under most drug frameworks the intended use communicated to buyers determines classification, so marketing SS-31 for human use or making therapeutic claims can trigger enforcement tools including warning letters, product seizure, injunctions, import alerts, and criminal referral.
Stepping outside the approval and prescribing system strips away nearly every safeguard a buyer would otherwise take for granted. Because the regulated supply chain never verified the vial, the full burden of judging what it contains lands on the purchaser.
A product outside the regulated supply chain carries no independent assurance of identity, purity, sterility, or accurate dosing, and the buyer absorbs the full burden of prescriber, pharmacist, and safety monitor without the training or tools of any.
Two labels get blurred here that are worth separating. A controlled or scheduled substance is one a government listed for abuse or dependence potential; an unapproved drug simply has not cleared the approval process, and the two categories do not automatically overlap. Anti-doping is a separate track again.
An unapproved drug is not automatically a controlled substance, so SS-31's main restriction flows from drug-approval law rather than scheduling, while anti-doping prohibited lists can capture it through catch-all categories for any athlete subject to testing.
The lawful routes to an investigational compound all run through sanctioned research rather than the open market. A general commercial purchase from a peptide vendor is not one of them, because selling an unapproved drug to the public for human use is exactly the activity the approval system prohibits.
The only lawful routes to SS-31 run through sanctioned research - enrollment in an authorized clinical trial or, more narrowly, an expanded-access arrangement agreed by the sponsor and regulator - while a commercial purchase from a peptide vendor is not a legitimate pathway.
Educational use only. This article describes what the published scientific and clinical literature reports about SS-31. It is not medical advice, and it does not recommend, prescribe, or tell anyone to use anything described here. The regulatory status shown at the top of this page reflects what the record showed on the date given there and can change. mdpep.com does not sell any substance described here, does not endorse human use of it, and does not direct anyone to obtain it.
This is not guidance for your situation. Nothing here accounts for your medical history, your current medications, or anything else specific to you, and none of it should be used to make a decision about your own health.
Affiliate disclosure. Some links on this site are affiliate links, and mdpep.com may earn a commission when they are used. That never affects what is written here, it is not an endorsement of any vendor, and it is not a statement that anything described on this page is available to buy.
Every claim here ties to a named primary source and a date, written as plain documentation with nothing for sale. That is how MD PEP covers the whole peptide market.
